跳转至内容
Merck
CN

SML0945

Sigma-Aldrich

Nilvadipine

≥98% (HPLC)

别名:

2-Cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-methyl 5-(1-methylethyl) ester, 5-Isopropyl-3-methyl-2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate, FK-235, FR-34235, Isopropyl 6-cyano-5-methoxycarbonyl-2-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate, Nivadipine, Nivaldipine, SKF-102362

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C19H19N3O6
化学文摘社编号:
75530-68-6
分子量:
385.37
UNSPSC代码:
12352200
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 15 mg/mL, clear

储存温度

room temp

SMILES字符串

[N+](=O)([O-])c1cc(ccc1)C2C(=C(NC(=C2C(=O)OC)C#N)C)C(=O)OC(C)C

InChI

1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3

InChI key

FAIIFDPAEUKBEP-UHFFFAOYSA-N

相关类别

一般描述

Nilvadipine is a dihydropyridine drug.

生化/生理作用

Nilvadipine is a potent calcium channel blocker that is used for treatment of hypertension. Nilvadipine, as other dihydropyridine calcium antagonists, decreases intracellular calcium concentration causing dilation of the coronary and systemic arteries. Nilvadipine acutely reduced brain Aβ levels in a transgenic mouse model of Alzheimer′s disease (AD).
Nilvadipine is a potent calcium channel blocker; antihypertensive; antianginal.
Nilvadipine, apart from its antihypertensive effect, is known to decrease the accumulation of β-amyloid protein in the brain. Therefore, it is effective in the treatment of Alzheimer′s disease. Nilvadipine also promotes cognitive function in hypertensive patients.

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H302

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000154812
0000154813
0000154812
0000125726

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.
Lawlor B, et al.
BMJ Open, 4(10), e006364-e006364 (2014)

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持